FDA approves Bausch Lomb drug

Jessica Perry//April 8, 2013

Bausch & Lomb, the Madison-based eye health company, today announced the U.S. Food and Drug Administration has approved the company’s new drug application for its Prolensa therapy.According to an announcement from the company, Prolensa is a once-daily drug to treat postoperative inflammation, and reduce pain, for patients who have undergone cataract surgery.